The effectiveness of lipid-lowering therapy in Poland - results of the OSLO-Pol study Original article
Article Sidebar
Published:
Sep 30, 2011
Keywords:
risk factors, dyslipidaemias, low-density lipoprotein, statins
Main Article Content
Abstract
Dyslipidemia is one of the most important modifiable risk factors for cardiovascular disease. Prevention and treatment of dyslipidaemias should always be considered within the broader framework of cardiovascular disease prevention. The aim of the present study was to evaluate the effectiveness of lipid-lowering therapy in a group of Polish patients with hyperlipidemia. The present results are the first report from the OSLO-Pol study.
Article Details
How to Cite
Filipiak , K. J., Szymański , F. M., Steciwko , A., & Opolski , G. (2011). The effectiveness of lipid-lowering therapy in Poland - results of the OSLO-Pol study. Medycyna Faktow (J EBM), 4(3(12), 6-11. Retrieved from https://journalsmededu.pl/index.php/jebm/article/view/2512
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Badacze Wieloośrodkowego Ogólnopolskiego Badania Stanu Zdrowia Ludności. Ogólnopolskie i regionalne rozpowszechnienie głównych czynników ryzyka układu sercowo-naczyniowego. Wyniki ogólnopolskiego badania stanu zdrowia ludności WOBASZ. Kardiol. Pol. 2005; 63: 614-685.
2. Zdrojewski T.: Prezentacja wyników badania NATPOL 2011. Konferencja prasowa w Polskiej Agencji Prasowej, Warszawa, 14.09.2011.
3. Opolski G., Filipiak K.J., Poloński L. (red.): Ostre zespoły wieńcowe. Wydawnictwo Urban & Partner, Wrocław 2002.
4. The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Guidelines for the management of dyslipidaemias. Eur. Heart J. 2011; 32: 1769-1818.
5. Pyörälä K., De Backer G., Graham I., Poole-Wilson P., Wood D.: Prevention of coronary heart disease in clinical practice: recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Atherosclerosis 1994; 110: 121-161.
6. Wood D., De Backer G., Faergeman O., Graham I., Mancia G., Pyörälä K.: Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention. Eur. Heart J. 1998; 19: 1434-1503.
7. De Backer G., Ambrosioni E., Borch-Johnsen K., Brotons C., Cifkova R., Dallongeville J., Ebrahim S., Faergeman O., Graham I., Mancia G., Cats V.M., Orth-Gomer K., Perk J., Pyörälä K., Rodicio J.L., Sans S., Sansoy V., Sechtem U., Silber S., Thomsen T., Wood D.: European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). Eur. J. Cardiovasc. Prev. Rehabil. 2003; 10: S1-S78.
8. Castelli W.P.: Epidemiology of coronary heart disease: the Framingham study. Am. J. Med. 1984; 76: 4-12.
9. O’Keefe J.H. Jr., Cordain L., Harris W.H., Moe R.M., Vogel R.: Optimal low-density lipoprotein is 50 to 70 mg/dl: lower is better and physiologically normal. J. Am. Coll. Cardiol. 2004; 43: 2142-2146.
10. Cholesterol Treatment Trialists’ (CTT) Collaboration; Baigent C., Blackwell L., Emberson J., Holland L.E., Reith C., Bhala N., Peto R., Barnes E.H., Keech A., Simes J., Collins R.: Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010; 376: 1670-1681.
2. Zdrojewski T.: Prezentacja wyników badania NATPOL 2011. Konferencja prasowa w Polskiej Agencji Prasowej, Warszawa, 14.09.2011.
3. Opolski G., Filipiak K.J., Poloński L. (red.): Ostre zespoły wieńcowe. Wydawnictwo Urban & Partner, Wrocław 2002.
4. The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Guidelines for the management of dyslipidaemias. Eur. Heart J. 2011; 32: 1769-1818.
5. Pyörälä K., De Backer G., Graham I., Poole-Wilson P., Wood D.: Prevention of coronary heart disease in clinical practice: recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Atherosclerosis 1994; 110: 121-161.
6. Wood D., De Backer G., Faergeman O., Graham I., Mancia G., Pyörälä K.: Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention. Eur. Heart J. 1998; 19: 1434-1503.
7. De Backer G., Ambrosioni E., Borch-Johnsen K., Brotons C., Cifkova R., Dallongeville J., Ebrahim S., Faergeman O., Graham I., Mancia G., Cats V.M., Orth-Gomer K., Perk J., Pyörälä K., Rodicio J.L., Sans S., Sansoy V., Sechtem U., Silber S., Thomsen T., Wood D.: European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). Eur. J. Cardiovasc. Prev. Rehabil. 2003; 10: S1-S78.
8. Castelli W.P.: Epidemiology of coronary heart disease: the Framingham study. Am. J. Med. 1984; 76: 4-12.
9. O’Keefe J.H. Jr., Cordain L., Harris W.H., Moe R.M., Vogel R.: Optimal low-density lipoprotein is 50 to 70 mg/dl: lower is better and physiologically normal. J. Am. Coll. Cardiol. 2004; 43: 2142-2146.
10. Cholesterol Treatment Trialists’ (CTT) Collaboration; Baigent C., Blackwell L., Emberson J., Holland L.E., Reith C., Bhala N., Peto R., Barnes E.H., Keech A., Simes J., Collins R.: Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010; 376: 1670-1681.